Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer
- Author(s)
- Blinman, P; Martin, A; Jefford, M; Goldstein, D; Boadle, D; Morris, M; Tebbutt, N; Aiken, C; Harkin, A; Segelov, E; Haydon, A; Iveson, T; Stockler, MR;
- Details
- Publication Year 2021,Volume 5,Issue #1,Page pkaa107
- Journal Title
- JNCI Cancer Spectrum
- Publication Type
- Research article
- Abstract
- BACKGROUND: SCOT was an international, randomized phase 3 trial of 3 months vs 6 months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in patients with colorectal cancer. We sought patients' preferences for 3 months vs 6 months of adjuvant chemotherapy in the SCOT trial. METHODS: SCOT participants from Australia and New Zealand completed a validated questionnaire (at 3 and 18 months) to elicit the minimum survival benefits judged necessary to make an extra 3 months of adjuvant chemotherapy worthwhile, based on their experience. Standardized hypothetical scenarios used the following baseline survivals (with 3 months of chemotherapy): life expectancies (LE) of 5 years and 15 years and 5-year survival rates (5YS) of 65% and 85%. RESULTS: Of the 160 participants, 82 were assigned 3 months adjuvant chemotherapy, and 78 were assigned 6 months. Adjuvant chemotherapy was FOLFOX in 121 (75.6%) and XELOX in 39 (24.4%). Preferences varied substantially and did not differ according to treatment group. The median survival benefits judged necessary to make the extra 3 months of chemotherapy worthwhile were an extra 3 years beyond a LE of 5 years; 3 years beyond a LE of 15 years; 15% beyond a 5YS of 65%; and 5% beyond a 5YS of 85%. Preferences were similar at 3 months and 18 months. Preferences were not predicted by participants' baseline characteristics. CONCLUSION: Preferences varied substantially, and the benefits many required to warrant an extra 3 months of adjuvant chemotherapy were larger than the benefits of an extra 3 months of chemotherapy calculated in the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) meta-analysis.
- Keywords
- Antineoplastic Combined Chemotherapy Protocols/*administration & dosage; Australia; Capecitabine/administration & dosage; Chemotherapy, Adjuvant/methods/statistics & numerical data; Colonic Neoplasms/*drug therapy/mortality; Drug Administration Schedule; Female; Fluorouracil/administration & dosage; Humans; Leucovorin/administration & dosage; Life Expectancy; Male; Middle Aged; New Zealand; Organoplatinum Compounds/administration & dosage; Oxaliplatin/administration & dosage; Oxaloacetates/administration & dosage; *Patient Preference; Prospective Studies; Surveys and Questionnaires; Survival Rate
- Department(s)
- Medical Oncology; Australian Cancer Survivorship Centre
- PubMed ID
- 34159294
- Publisher's Version
- https://doi.org/10.1093/jncics/pkaa107
- Open Access at Publisher's Site
https://doi.org/10.1093/jncics/pkaa107- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-06-13 06:47:59
Last Modified: 2025-06-13 06:48:45